Clinical Trials for Geroprotectors and Deep Immunological Aging Clocks to Combat COVID-19

The Biogerontology Research Foundation announced the publication of an important paper by Alex Zhavoronkov, PhD, the chief scientist of the Biogerontology Research Foundation and the CEO of an Insilico Medicine. In the paper Alex Zhavoronkov proposes a strategy for repurposing known geroprotectors such as rapamycin, nicotinamide riboside, nicotinamide mononucleotide, metformin, and other drugs with the known safety profile for prevention of COVID-19 in older people. There are over 1 billion people over 60 in the world and they are the demographic that’s most vulnerable to the virus.


Posted in Coronavirus Articles.